Krebs Biochemicals & Industries (NSE:KREBSBIO) Debt-to-Asset : 1.38 (As of Mar. 2026)


NSE:KREBSBIO Krebs Biochemicals & Industries Ltd NSE:KREBSBIO
38 GF Score
Price ₹65.45
GF Value ₹38.67
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Krebs Biochemicals & Industries Debt-to-Asset?

Krebs Biochemicals & Industries NSE:KREBSBIO +1.38% 38 Debt-to-Asset is 1.38 as of Mar. 2026. GuruFocus rates NSE:KREBSBIO with a GF Score™ of 38/100 and a GF Value™ of ₹38.67 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Krebs Biochemicals & Industries's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was ₹612.9 Mil. Krebs Biochemicals & Industries's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was ₹1,635.5 Mil. Krebs Biochemicals & Industries's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was ₹1,632.5 Mil. Krebs Biochemicals & Industries's debt to asset for the quarter that ended in Mar. 2026 was 1.38.

Krebs Biochemicals & Industries  (NSE:KREBSBIO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Krebs Biochemicals & Industries Debt-to-Asset Related Terms

Krebs Biochemicals & Industries Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Krebs Biochemicals & Industries's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krebs Biochemicals & Industries Debt-to-Asset Chart

Krebs Biochemicals & Industries Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 1.31 1.34 1.52 1.38

Krebs Biochemicals & Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 0.00 1.31 1.34 1.38

NSE:KREBSBIO vs ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Krebs Biochemicals & Industries's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krebs Biochemicals & Industries Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Krebs Biochemicals & Industries's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Krebs Biochemicals & Industries's Debt-to-Asset falls into.


NSE:KREBSBIO
38GF Score
Krebs Biochemicals & Industries Ltd NSE:KREBSBIO
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krebs Biochemicals & Industries Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Krebs Biochemicals & Industries's Debt-to-Asset for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(612.882 + 1635.5) / 1632.467
=1.38

Krebs Biochemicals & Industries's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(612.882 + 1635.5) / 1632.467
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 1.38 mean?
Krebs Biochemicals & Industries (NSE:KREBSBIO) has a Debt-to-Asset of 1.38 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Krebs Biochemicals & Industries and its competitors.
Is Krebs Biochemicals & Industries' Debt-to-Asset too high?
Krebs Biochemicals & Industries' current Debt-to-Asset is 1.38. Overall, Krebs Biochemicals & Industries has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krebs Biochemicals & Industries' Debt-to-Asset compare to ZTS?
Krebs Biochemicals & Industries' Debt-to-Asset of 1.38 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Krebs Biochemicals & Industries and its competitors. Krebs Biochemicals & Industries's current Debt-to-Asset is 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krebs Biochemicals & Industries stock overvalued right now?
Based on GuruFocus' analysis, Krebs Biochemicals & Industries (NSE:KREBSBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹38.67, compared to a current price of ₹65.45 — trading 69.3% above its estimated fair value. The current Debt-to-Asset is 1.38. Krebs Biochemicals & Industries' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Krebs Biochemicals & Industries (NSE:KREBSBIO), the current Debt-to-Asset is 1.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krebs Biochemicals & Industries (NSE:KREBSBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Krebs Biochemicals & Industries stock appears to be overvalued. The current stock price of ₹65.45 is trading 69.3% above its estimated GF Value™ of ₹38.67. GuruFocus considers Krebs Biochemicals & Industries to be Significantly Overvalued.

Key valuation signals for NSE:KREBSBIO:

  • Debt-to-Asset: 1.38
  • GF Value™: ₹38.67 vs. price of ₹65.45 (69.3% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the NSE:KREBSBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krebs Biochemicals & Industries Business Description

Other Exchanges 524518:India
Address Kothapalli Village, Kasimkota Mandal, Anakapalli, Vishakapatnam, AP, IND, 531 031
Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.
38GF Score

Get the complete analysis for NSE:KREBSBIO

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹65.45
Price
₹38.67
GF Value